# Delcath Systems

Type: Company (DCTH)

Source: GetYourBrief — https://getyourbrief.com/entity/delcath-systems
Canonical HTML page: https://getyourbrief.com/entity/delcath-systems

## Recent coverage (5 stories, network-wide)

### Retail and Fintech Earnings Preview: Gildan and Payoneer Lead Q4 Outlook
2026-02-25 17:24:31 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 9

The Q4 2025 earnings cycle highlights a critical juncture for apparel manufacturing and cross-border e-commerce. Gildan Activewear and Payoneer Global serve as key bellwethers for consumer demand and global trade efficiency.
Full story: https://getretailbrief.com/story/retail-ecommerce-q4-2025-earnings-preview-gildan-payoneer

### Delcath and Bentley Lead Q4 Earnings Previews in Cloud-Enabled Health & Infra
2026-02-25 16:00:58 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 6

A wave of Q4 2025 earnings previews highlights the growing intersection of specialized SaaS platforms and high-stakes medical and infrastructure sectors. Companies like Delcath Systems and Bentley Systems are under scrutiny as investors look for evidence of commercial scaling and software-driven efficiency gains.
Full story: https://getsaasbrief.com/story/delcath-bentley-q4-2025-earnings-preview

### Biotech Earnings Preview: Delcath, Butterfly, Heron, and Lantheus Set Q4 Outlook
2026-02-25 15:07:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.
Full story: https://getfinancebrief.com/story/biotech-medtech-q4-2025-earnings-preview

### Q4 2025 Biotech Earnings: Delcath and Peers Face Critical Commercial Milestones
2026-02-25 15:07:22 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Full story: https://getbiobrief.com/story/biotech-pharma-q4-2025-earnings-preview-delcath-lantheus

### MedTech and Specialty Pharma Braced for High-Stakes Q4 2025 Results
2026-02-25 15:05:48 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Delcath Systems, Lantheus Holdings, Butterfly Network, and Heron Therapeutics are preparing to report Q4 2025 earnings, marking a critical test for commercial-stage medical innovators. Investors are laser-focused on the adoption rates of flagship products like HEPZATO KIT and PYLARIFY as these companies navigate a complex reimbursement environment.
Full story: https://gethealthbrief.com/story/medtech-specialty-pharma-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.